Selecta Biosciences (SELB) Tops Q2 EPS by 14c

Selecta Biosciences (NASDAQ: SELB) reported Q2 EPS of $0.06, $0.14 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $39.27 million versus the consensus estimate of $13.78 million.

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c